Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neuroectodermal Tumors, Primitive 2 Uterine Neoplasms 1 Tuberous Sclerosis 1 Perivascular Epithelioid Cell Neoplasms 1 Neuroendocrine Tumors 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Breast Neoplasms 1 Angiomyolipoma 1

Interventions

pembrolizumab 31 Gemcitabine 26 Nivolumab 20 atezolizumab 16 Cisplatin 15 avelumab 14 Carboplatin 12 Docetaxel 10 enfortumab vedotin 8 Magnetic Resonance Spectroscopy 8 durvalumab 7 Specimen Handling 7 Paclitaxel 7 Ipilimumab 6 toripalimab 5 pemigatinib 5 cabozantinib 5 vinflunine 4 sacituzumab govitecan 4 Taxes 4 Pemetrexed 4 tislelizumab 3 cabazitaxel 3 Standard of Care 3 Mitomycin 3 Injections 3 Everolimus 3 Albumin-Bound Paclitaxel 3 sapanisertib 2 olaparib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Transitional Cell × dactolisib × Clear all

NCT01856101 2019-04-10

BEZ235

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 2 Terminated

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡